Table 5Estimated 3-Year Risk Difference for MACE and ACM Among SU Second-Line Users

OutcomeMethodSU vs DPP-4 Inhibitor, % (SE)SU vs TZD, % (SE)
MACE ABB, no subclasses1.6 (0.8)4.6 (0.8)
ABB, 3 subclasses0.1 (0.8)4.4 (0.9)
ABB, 5 subclasses0.1 (0.9)3.7 (0.9)
7 subclasses0.1 (0.9)3.5 (0.9)
Matching−0.1 (0.8)3.6 (1.0)
IPW−0.4 (0.8)3.2 (0.9)
ACM ABB, no subclasses1.6 (0.4)0.7 (0.5)
ABB, 3 subclasses1.2 (0.4)0.4 (0.6)
ABB, 5 subclasses1.2 (0.5)0.3 (0.6)
7 subclasses1.1 (0.4)0.5 (0.5)
Matching0.9 (0.4)0.5 (0.6)
IPW0.9 (0.4)0.3 (0.5)

Abbreviations: ABB, approximate Bayesian bootstrap; ACM, all-cause mortality; DPP-4, dipeptidyl peptidase-4; IPW, inverse probability weighting; MACE, major adverse cardiovascular events; SU, sulfonylurea; TZD, thiazolidinedione.

From: Creating and Testing Methods to Estimate Treatment Effect in Observational Studies with Three or More Treatments

Cover of Creating and Testing Methods to Estimate Treatment Effect in Observational Studies with Three or More Treatments
Creating and Testing Methods to Estimate Treatment Effect in Observational Studies with Three or More Treatments [Internet].
Gutman R, Scotina A, Smith RJ, et al.
Copyright © 2020. Brown University. All Rights Reserved.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License which permits noncommercial use and distribution provided the original author(s) and source are credited. (See https://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.